UroGen Pharma Ltd. Ordinary Shares
$43.63
$0.14 (+0.32%)
$43.15Day Range$45.33
Key Statistics
Market Cap
$2.13B
Shares Outstanding
48.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 4, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$44.82
Day High
$45.33
Day Low
$43.15
Volume
370.4K
VWAP
$44.52
Prev Close
$43.49
Transactions
--
Acc. Volume
--
About UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
PHARMACEUTICAL PREPARATIONSSIC 2834291 employees9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007972 9 770 7601IPO May 4, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001668243
- Ticker Root
- URGN
- SIC Code
- 2834
About UroGen Pharma Ltd. Ordinary Shares (URGN) Stock
UroGen Pharma Ltd. Ordinary Shares (URGN) closed the 2026-09-17 session at $43.63, up 0.32% versus the previous close (+0.14). The stock opened at $44.82 and traded between $43.15 and $45.33 during that session. Session trading volume was 370K shares. The volume-weighted average price (VWAP) is $44.52.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
UroGen Pharma Ltd. Ordinary Shares has a market capitalization of $2.13 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. URGN is listed on the XNAS exchange. The company employs approximately 291 people. UroGen Pharma Ltd. Ordinary Shares is headquartered in RA'ANANA, L3. The recorded listing date is 2017-05-04.
On this page you can find market URGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.